RxDoctor Payments Data

Dharam Anand, MD

Internal Medicine · Bourbonnais, ILNPI 1134107170

Payments from drug & device makers

$11,459in general payments, 2019–2025

Across 847 payments — averaging $13.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Nestle Healthcare Nutrition Inc.$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$673
  • AstraZeneca$521
  • Otsuka America Pharmaceutical, Inc.$520
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$11,37799%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,459 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$186,704
Medicare patients
343
Services billed
2,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$118,608
MounjaroTirzepatide59$85,117
Austedo XrDeutetrabenazine12$71,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$58,683
EliquisApixaban83$52,106
JanuviaSitagliptin Phosphate64$50,920
TrulicityDulaglutide40$45,135
JardianceEmpagliflozin54$33,936
Tresiba Flextouch U-100Insulin Degludec23$31,272
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$30,819
Tresiba Flextouch U-200Insulin Degludec25$25,135
LinzessLinaclotide18$17,411
RybelsusSemaglutide12$16,526
SymbicortBudesonide/Formoterol Fumarate34$14,318
XareltoRivaroxaban15$12,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,048$135,134115 claims
Lilly USA, LLCMounjaro, Trulicity$673$130,25299 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$485$71,99012 claims
GSKTrelegy Ellipta, Breo Ellipta$224$64,63398 claims
MerckJanuvia, Janumet$128$62,34676 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$215$52,58181 claims
PfizerEliquis$216$52,10683 claims
AbbVieLinzess, Creon$2,213$26,97730 claims
AstraZenecaSymbicort$521$14,31834 claims
Johnson & JohnsonXarelto$196$12,50415 claims
Sanofi-aventis U.S. LLCAdmelog$104$11,63412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Bourbonnais

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →